EUVIMEDEUVIMED entdecken
Crossref

Evaluating alloimmunization risk in patients with sickle cell disease and in prenatal care patients with RHCE variants

Gabriel André Leiva-Torres iD, Nadia Baillargeon, Jessica Constanzo-Yanez, Nancy Robitaille

Vox Sanguinis · 2026

DOI: 10.1111/vox.70193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2026. Verfasst von Gabriel André Leiva-Torres und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hema-Quebec, Transfusion Medicine, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Rh-Hr Blood-Group System, Isoantibodies, Prenatal Care. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Clinically significant alloantibodies complicate transfusion and prenatal care, especially in individuals with genetic variants affecting high‐frequency antigens. Many patients from African descent carry RHCE*ceVS alleles, which alter the expression of c (RH4), e (RH5) and hr B (RH31). However, the risk and clinical impact of alloimmunization remain uncertain. We evaluated the alloimmunization in a cohort of patients with a RHCE*ceVS genotype. Materials and Methods We conducted a retrospective study on 48 patients with a RHCE*ceVS genotype divided into three categories: prenatal care, patients with sickle cell disease (SCD) and other or unspecified diagnosis.

Results

No anti‐c, anti‐e or anti‐hr B were found in prenatal care patients or in patients with other or unspecified diagnosis. Among transfused patients with SCD, 50% developed an anti‐e. Anti‐hr B was identified in two patients, both with SCD. Warm autoantibodies were found in 58% of transfused patients with SCD, many of whom had an anti‐e.

Conclusion

The risk of developing anti‐e or anti‐hr B antibodies was low in patients with an RHCE*ceVS genotype, except in those with SCD. In patients with SCD, the presence of autoantibodies, recent transfusions and technical caveats complicate the assessment of clinical impact; therefore, an individualized evaluation of alloimmunization risk is recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellRh-Hr Blood-Group SystemIsoantibodiesPrenatal CareRh IsoimmunizationHumansFemaleRetrospective StudiesPregnancyAdultMaleGenotype

Stichwörter der Autor:innen

RHCEalloimmunizationprenatal caresickle cell disease

Substanzen

Rh-Hr Blood-Group SystemIsoantibodiesRHCE protein, human

Autor:innen und Institutionen

  • Hema-Quebec, Transfusion Medicine, Montreal, Québec, Canada.
  • Division of Hematology-Oncology, Department of Pediatrics, CHU Sainte-Justine, Montreal, Québec, Canada.

ORCID-Profile: Gabriel André Leiva-Torres

Zitieren

APA

Leiva-Torres, G. A., Baillargeon, N., Constanzo-Yanez, J., & Robitaille, N. (2026). Evaluating alloimmunization risk in patients with sickle cell disease and in prenatal care patients with RHCE variants. Vox Sanguinis. https://doi.org/10.1111/vox.70193

Vancouver

Leiva-Torres GA, Baillargeon N, Constanzo-Yanez J, Robitaille N. Evaluating alloimmunization risk in patients with sickle cell disease and in prenatal care patients with RHCE variants. Vox Sanguinis. 2026. doi:10.1111/vox.70193

BibTeX
@article{LeivaTorres2026,
  author = {Leiva-Torres, Gabriel André and Baillargeon, Nadia and Constanzo-Yanez, Jessica and Robitaille, Nancy},
  title = {Evaluating alloimmunization risk in patients with sickle cell disease and in prenatal care patients with RHCE variants},
  journal = {Vox Sanguinis},
  year = {2026},
  doi = {10.1111/vox.70193}
}
Kostenlos starten →